Shots:

• The P-III (VISION-2) study evaluates the safety & efficacy of MicroLine vs PBO in patients (n=140) with presbyopia randomly assigned in groups receiving a 2% dosing of MicroLine vs PBO
• The results demonstrated that the study met its 1EP depicting a ≥15-letter improvement in distance corrected near visual acuity with ≤5-letter loss in distance acuity vs PBO in low light conditions @2hrs. post-treatment. The study also met all 2EPs at a statistically significant level
• MicroLine is a pilocarpine ophthalmic solution developed for the treatment of presbyopia. Additionally, Eyenovia expects to submit an NDA application for the approval of MicroLine to the US FDA within its planned commercialization timeline

Ref: GlobeNewswire | Image: Businesswire